Andrew Ashe serves as President, COO, and General Counsel at Verve Therapeutics since August 2018. Prior to this role, Andrew Ashe was General Counsel at AGTC from August 2017 to August 2018 and held various positions at Dyax from June 2003 to January 2016, including Executive Vice President of Operations and General Counsel. Andrew Ashe's career also includes experience as an attorney at Prince Lobel Tye LLP and Nutter, as well as roles in trading and analysis at the American Stock Exchange and New York Stock Exchange. Andrew Ashe earned a Doctor of Law (JD) from The George Washington University Law School and a Bachelor of Business Administration (B.B.A.) in Finance/Economics from the Isenberg School of Management at UMass Amherst.
Sign up to view 7 direct reports
Get started